Binding of Ru(bpy)2(eilatin)2+ to matched and mismatched DNA

Emerging pharmaceutical therapies of Ascidian-derived natural products and derivatives

In a growing multidrug-resistant environment, the identification of potential new drug candidates with an acceptable safety profile is a substantial crux in pharmaceutical discovery. This review discusses several aspects and properties of approved marine natural products derived from ascidian sources (phylum Chordata, subphylum Tunicata) and/or their deduced analogues including their biosynthetic origin, (bio)chemical preclinical assessments and known efficacy-safety profiles, clinical status in trials, but also translational developments, opportunities and final conclusions. The review also describes the preclinical assessments of a large number of other ascidian compounds that have not been involved in clinical trials yet. Finally, the emerging research on the connectivity of the ascidian hosts and their independent or obligate symbiotic guests is discussed. The review covers the latest information on the topic of ascidian-derived marine natural products over the last two decades including 2022, with the majority of publications published in the last decade.

Evaluation of 1 H-NMR Spectroscopy-Based Quantification Methods of the Supramolecular Aggregation of a Molecular Photosensitizer

The supramolecular dimerization of a ruthenium polypyridyl precursor of a well-developed family of hydrogen evolving photocatalysts via π-π-interactions of the polyheteroaromatic bridging ligand was quantified with concentration dependent ¹ H-NMR-spectroscopy. The data sets were analyzed with different calculation and fit methods. A comparison between the results of direct calculation, linear and nonlinear approaches showed that the application of a global nonlinear fit procedure yields the best results. The presented methods are also applicable for dimerization processes in solution of other molecular moieties.

Structural insights into the recognition of DNA defects by small molecules

Studies on the binding interaction of small molecules and nucleic acids have been explored for their biological applications. With excellent photophysical/chemical properties, numerous metal complexes have been studied as structural probes for nucleic acids. The recognition of DNA defects is of high importance due to their association with various types of cancers. Small molecules that target DNA defects in a specific and selective manner offer a new avenue for developing novel drugs and diagnostic tools. Transition metal complexes have been studied as probes for abasic sites and DNA/RNA mismatches. By changing the ligand structure or metal center, the probing efficiency of the metal complexes varies towards the defects. In this perspective, we have discussed mainly the structural requirement of metal complexes as probes for abasic sites, mismatches, and covalent DNA adducts, followed by the challenges and future directions.

A Ruthenium(II) Complex as a Luminescent Probe for DNA Mismatches and Abasic Sites

[Ru(bpy)₂(BNIQ)]²⁺ (BNIQ = Benzo[c][1,7]naphthyridine-1-isoquinoline), which incorporates the sterically expansive BNIQ ligand, is a highly selective luminescent probe for DNA mismatches and abasic sites, possessing a 500-fold higher binding affinity toward these destabilized regions relative to well-matched base pairs. As a result of this higher binding affinity, the complex exhibits an enhanced steady-state emission in the presence of DNA duplexes containing a single base mismatch or abasic site compared to fully well-matched DNA. Luminescence quenching experiments with Cu(phen)₂²⁺ and [Fe(CN)₆]^3– implicate binding of the complex to a mismatch from the minor groove via metalloinsertion. The emission response of the complex to different single base mismatches, binding preferentially to the more destabilized mismatches, is also consistent with binding by metalloinsertion. This work shows that high selectivity toward destabilized regions in duplex DNA can be achieved through the rational design of a complex with a sterically expansive aromatic ligand.

The luminescent complex [Ru(bpy)₂(BNIQ)]²⁺ selectivity targets mismatched and abasic sites in duplex DNA and exhibits an enhanced emission intensity in the presence of these defect sites relative to well-matched base pairs.

Bifunctional Zn(II) complexes for recognition of non-canonical thymines in DNA bulges and G-quadruplexes

Six Zn(II) complexes of derivatives of 1,4,7,10-tetraazacyclododecane (cyclen) were studied for binding to DNA sequences containing non-canonical thymines, including a hairpin with a single thymine bulge (T-bulge) and a G-quadruplex (H-telo) containing thymine loops. The cyclen-based macrocycles contained pendents with either two fused rings to give planar groups including quinolinone (QMC), coumarin (MCC) and quinoline (CQC) derivatives or a non-planar dansyl group (DSC). Macrocyclic complexes with three fused rings including an anthraquinone pendent (ATQ) were also studied. All Zn(II) complexes were stable in solution at micromolar concentrations and neutral pH with the Zn(L)(OH2) species prevailing for L = QMC and CQC at pH 7.5 and 100 mM NaCl. Immobilized T-bulge or H-telo G-quadruplex was used to study binding of the complexes by surface plasmon resonance (SPR) for several of the complexes. For the most part, data matched well with that obtained by isothermal calorimetry (ITC) and, for fluorescent complexes, by fluorescence titrations. Data showed that Zn(II) complexes containing planar aromatic pendents with two fused rings bound to T-bulge more tightly than complexes with non-planar pendents such as DSC. The H-telo DNA exhibited multiple binding sites for all complexes containing aromatic pendents. The complexes with two fused rings bound with low micromolar dissociation constants and two binding sites whereas a complex with three fused rings (ATQ) bound to three sites. This study shows that different pendent groups on Zn(II) cyclen complexes impart selectivity for recognition of non-canonical DNA structures.

A mini review on pyridoacridines: Prospective lead compounds in medicinal chemistry

Natural products are increasingly being considered “critical and important” in drug discovery paradigms as a number of them such as camptothecin, penicillin, and vincristine serve as “lead molecules” for the discovery of potent compounds of therapeutic interests namely irinotecan, penicillin G, vinblastine respectively. Derived compounds of pharmacological interests displayed a wide variety of activity viz. anticancer, anti-inflammatory, antimicrobial, anti-protozoal, etc.; when modifications or derivatizations are performed on a parent moiety representing the corresponding derivatives. Pyridoacridine is such a moiety which forms the basic structure of numerous medicinally important natural products such as, but not limited to, amphimedine, ascididemin, eilatin, and sampangine. Interestingly, synthetic analogues of natural pyridoacridine exhibit diverse pharmacological activities and in view of these, natural pyridoacridines can be considered as “lead compounds”. This review additionally provides a brief but critical account of inherent structure activity relationships among various subclasses of pyridoacridines. Furthermore, the current aspects and future prospects of natural pyridoacridines are detailed for further reference and consideration.

Luminescent properties of ruthenium(II) complexes with sterically expansive ligands bound to DNA defects

A new family of ruthenium(II) complexes with sterically expansive ligands for targeting DNA defects was prepared, and their luminescent responses to base pair mismatches and/or abasic sites were investigated. Design of the complexes sought to combine the mismatch specificity of sterically expansive metalloinsertors, such as [Rh(bpy)2(chrysi)](3+) (chrysi = chrysene-5,6-quinone diimine), and the light switch behavior of [Ru(bpy)2(dppz)](2+) (dppz = dipyrido[3,2-a:2',3'-c]phenazine). In one approach, complexes bearing analogues of chrysi incorporating hydrogen-bonding functionality similar to dppz were synthesized. While the complexes show luminescence only at low temperatures (77 K), competition experiments with [Ru(bpy)2(dppz)](2+) at ambient temperatures reveal that the chrysi derivatives preferentially bind DNA mismatches. In another approach, various substituents were introduced onto the dppz ligand to increase its steric bulk for mismatch binding while maintaining planarity. Steady state luminescence and luminescence lifetime measurements reveal that these dppz derivative complexes behave as DNA "light switches" but that the selectivity in binding and luminescence with mismatched/abasic versus well-matched DNA is not high. In all cases, luminescence depends sensitively upon structural perturbations to the dppz ligand.

Synthesis, DNA-binding and photocleavage of "light switch" complexes [Ru(bpy)2(pyip)]2+ and [Ru(phen)2(pyip)]2+

Two novel Ru(II) complexes [Ru(bpy)(2)(pyip)](2+)1 and [Ru(phen)(2)(pyip)](2+)2 (bpy=2,2'-bipyridine; phen=1,10-phenanthroline; pyip=2-(pyridine-2-yl)imidazo-[4,5-f][1,10]-phenanthroline), have been synthesized and characterized by elemental analysis, ES-MS, (1)H NMR, UV-Vis. The DNA-binding behaviors of both complexes were studied by spectroscopic methods and viscosity measurements. The results indicate that the two complexes can bind to CT-DNA in an intercalative mode, and also show that these two Ru(II) complexes can promote the photocleavage of pBR322 DNA. In addition, In the presence of Co(2+), the emission of DNA-[Ru(L)(2)pyip](2+) can be quenched, which exhibited the DNA "light switch" properties.

Macrocyclic DNA-mismatch-binding ligands: structural determinants of selectivity

A collection of 15 homodimeric and 5 heterodimeric macrocyclic bisintercalators was prepared by one- or two-step condensation of aromatic dialdehydes with aliphatic diamines; notably, the heterodimeric scaffolds were synthesized for the first time. The binding of these macrocycles to DNA duplexes containing a mispaired thymine residue (TX), as well as to the fully paired control (TA), was investigated by thermal denaturation and fluorescent-intercalator-displacement experiments. The bisnaphthalene derivatives, in particular, the 2,7-disubstituted ones, have the highest selectivity for the TX mismatches, as these macrocycles show no apparent binding to the fully paired DNA. By contrast, other macrocyclic ligands, as well as seven conventional DNA binders, show lesser or no selectivity for the mismatch sites. The study demonstrates that the topology of the ligands plays a crucial role in determining the mismatch-binding affinity and selectivity of the macrocyclic bisintercalators.

Synthesis, Characterization, and DNA Binding Studies of Ruthenium(II) Complexes with 2-Pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione

Three novel asymmetric ruthenium(ii) complexes, [Ru(bpy)2(PAIDH)]2+ 1, [Ru(phen)2(PAIDH)]2+ 2, and [Ru(dmp)2(PAIDH)]2+ 3 (bpy = 2,2′-bipyridine, phen = 1,10-phenanthroline, dmp = 2,9-dimethyl-1,10-phenanthroline, PAIDH = 2-pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione), have been synthesized and characterized. The structure of the deprotonated complex [Ru(dmp)2(PAID)]+ 4 has been determined by single-crystal X-ray diffraction techniques, and the anthraquinone moiety is approximately coplanar with the imidazole ring. The DNA binding properities of complexes 1, 2, and 3 to calf-thymus DNA (CT-DNA) were investigated. Spectroscopic studies and viscosity experiments suggest that the RuII complexes intercalate into DNA base pairs by the extended anthraquinone unit, and the ancillary ligands have significant effects on the spectroscopic properties and DNA binding behaviour of the RuII complexes.